Division of Urology, Department of Surgical, Oncological, and Oral Sciences, University of Palermo, Palermo, Italy,
Division of Urology, Department of Surgical, Oncological, and Oral Sciences, University of Palermo, Palermo, Italy.
Urol Int. 2020;104(5-6):396-401. doi: 10.1159/000507122. Epub 2020 May 5.
Evidence that smoking cessation at first diagnosis of nonmuscle-invasive bladder cancer (NMIBC) reduces the risk of recurrence is lacking. The aim of our prospective study was to analyze the association between patients' changes in smoking habits after diagnosis and recurrence-free survival (RFS).
After transurethral resection of primary NMIBC, patients were classified as "ex-smokers," i.e., those definitively stopping, and as "active smokers," i.e., those continuing or restarting to smoke. Smoking status was reassessed every 3 months during the first year and every 6 months thereafter. Data on patients' demographics, smoking status, tumor characteristics, treatments, and follow-up were collected. Statistical analysis was performed adopting SPSS 15.0.1 and R3.4.2 software.
Out of 194 patients, 67 (34.5%) quit smoking after the diagnosis, while 127 (65.5%) did not. The clinical and pathological characteristics were homogeneously distributed. At a median follow-up of 38 months, 106 patients (54.6%) recurred, 33 (49.2%) ex- and 73 (60.3%) active smokers with a 3-year RFS of 42.3 and 50.7%, respectively (p = 0.55). No statistically significant association between recurrence, pathological features of the primary tumor, and patient smoking habits after diagnosis was detected. Results were not statistically influenced by the intensity (cigarette/day) and duration (years) of smoking. In multivariate analysis, cigarette smoking cessation at diagnosis did not significantly reduce tumor recurrence.
In our prospective study, more than half of our patients recurred at 3 years. In multivariate analysis, smoking cessation did not significantly reduce tumor recurrence. However, the 8.4% reduction in favor of the ex-smokers suggests the need of larger studies with longer follow-ups. Surprisingly, only 35% of smokers definitively quit after diagnosis. The urologists should play a more active role to persuade the patients to stop smoking at first cancer diagnosis.
目前缺乏证据表明非肌肉浸润性膀胱癌(NMIBC)初诊时戒烟可降低复发风险。我们前瞻性研究的目的是分析患者诊断后吸烟习惯的变化与无复发生存率(RFS)之间的关系。
经尿道切除原发性 NMIBC 后,患者被分为“戒烟者”,即明确戒烟者,以及“吸烟者”,即继续或重新开始吸烟的患者。在第 1 年的前 3 个月和之后的每 6 个月,吸烟状况会重新评估。收集患者的人口统计学、吸烟状况、肿瘤特征、治疗和随访数据。采用 SPSS 15.0.1 和 R3.4.2 软件进行统计分析。
在 194 例患者中,67 例(34.5%)在诊断后戒烟,而 127 例(65.5%)未戒烟。临床和病理特征分布均匀。在中位随访 38 个月时,106 例(54.6%)患者复发,其中 33 例(49.2%)为戒烟者,73 例(60.3%)为吸烟者,3 年 RFS 分别为 42.3%和 50.7%(p = 0.55)。未发现复发与肿瘤的主要病理特征以及患者诊断后吸烟习惯之间存在统计学显著关联。结果不受吸烟强度(每天香烟数)和吸烟时间(年)的影响。多变量分析显示,诊断时戒烟并不能显著降低肿瘤复发。
在我们的前瞻性研究中,超过一半的患者在 3 年内复发。多变量分析显示,戒烟并不能显著降低肿瘤复发。然而,戒烟者复发风险降低了 8.4%,这表明需要进行更大规模、随访时间更长的研究。令人惊讶的是,只有 35%的吸烟者在诊断后明确戒烟。泌尿科医生应发挥更积极的作用,说服患者在首次确诊癌症时戒烟。